KEYTRUDA, generically known as pembrolizumab, is a groundbreaking immunotherapy medication used in the treatment of various types of cancer. It operates by enhancing the body's immune system to help it detect and fight cancer cells more effectively. KEYTRUDA is particularly known for its use in treating melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and certain types of bladder and kidney cancers, among others. It is administered through intravenous infusion and works by targeting and inhibiting the PD-1 pathway, a protein on the surface of cells that helps keep the body's immune responses in check. By blocking this pathway, KEYTRUDA helps the immune system to attack cancer cells more vigorously. Its use marks a significant advancement in cancer therapy, offering hope to many patients with previously limited treatment options. When using KEYTRUDA, it is crucial to take certain precautions to ensure your safety and the effectiveness of the treatment. KEYTRUDA can cause side effects that may impair your ability to drive or operate machinery safely. Common side effects include fatigue, nausea, and skin rash, while rare but serious side effects can include immune system reactions affecting organs like the lungs, liver, endocrine glands, or intestines. It is of utmost importance to follow your doctor's instructions closely and to read the label that comes with the medicine for detailed information on usage and potential side effects. Additionally, inform your doctor about all other medications you are taking, as KEYTRUDA can interact with other drugs, potentially leading to adverse effects. Always prioritize communication with your healthcare provider to navigate any concerns or symptoms you experience while on KEYTRUDA therapy.
Your cart contains products from a separate order category. Adding this product will remove those items from your cart.
Important Supply & Pricing Update about GLP-1 Medications
Due to manufacturer-driven price increases from Eli Lilly and other suppliers, prices for GLP-1 medications including Mounjaro have risen significantly. Global supply constraints may also result in slightly longer lead times.
We remain committed to securing the best possible pricing and supply for our customers and will continue to provide updates as the situationĀ evolves.